Shares of Cassava Sciences moved higher after the United States Patent and Trademark Office posted a patent allowance for an Alzheimer’s disease assay in a living patient. The stock in midday trading is up 2% to $22.26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Cassava Sciences call volume above normal and directionally bullish
- Cassava Sciences price target raised to $131 from $124 at H.C. Wainwright
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
- Cassava Sciences reports Q1 EPS (43c), two estimates (46c)
- Cassava Sciences (NASDAQ:SAVA): Cracking Alzheimer’s or Succumbing to Short Sellers?